[Granulometry and measurement of a aerosol drug deposit (fusafungine) in normal and pathological airways].
We measured with a laser velocimeter granulometric deposit of an aerosol anti-infectious agent, fusafungin, administered with a controlled inhalator. Total drug deposit was determined on the basis of a granulometric spectrum of the polydispered aerosol (mass mean aerodynamic diameter (MMAD) = 2.8 +/- 1.7 microns) and dispersion in the airways was estimated using the Stahlhofen model. We first compared deposits obtained with oral inhalation in 19 normal subjects and 20 patients with chronic obstructive lung disease. Total deposit in the airways of patients with chronic obstructive lung disease (82%) was not significantly different from that in normal subjects (85%). Estimated dispersion in normal airways was 27% in the alveoles, 8.4% in the tracheobronchic region and 23.5% in the extrathoracic regions. We then compared deposits after nasal inhalation in 22 normal subjects and 21 patients with rhinitis: nasal deposit was significantly greater in patients with rhinitis (54.5%) than in controls (44.7%). We conclude that such an inhalator can be adapted for local treatment of ENT infections and upper respiratory infections. Deposit is not modified in case of obstructive bronchopathy.
Bouchikhi
A
A
Service Central d'Explorations Fonctionnelles Respiratoires, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Becquemin
M H
MH
Bertholon
J F
JF
Roy
M
M
Harpey
C
C
Stahlhofen
W
W
Nizar
Z
Z
D000328:Adult; D000336:Aerosols / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D047630:Depsipeptides; D005670:Fusarium; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000503:physiopathology; D008875:Middle Aged; D008954:Models, Biological; D009666:Nose; D010316:Particle Size; D012106:Research; D012212:Rheology; D012220:Rhinitis / Q000503:physiopathology
D000336:Aerosols; D000900:Anti-Bacterial Agents; D047630:Depsipeptides; C014001:fusafungin